Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy
Introduction. Helicobacter pylori eradication therapy has the potential burden of antibiotic-associated gastrointestinal (GI) side effects. The occurrence of side effects is among the major drawbacks of such regimens. GI manifestations may be related to alterations in the intestinal microflora. Prob...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/740381 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562626425520128 |
|---|---|
| author | Veronica Ojetti Giovanni Bruno Maria Elena Ainora Giovanni Gigante Gianluca Rizzo Davide Roccarina Antonio Gasbarrini |
| author_facet | Veronica Ojetti Giovanni Bruno Maria Elena Ainora Giovanni Gigante Gianluca Rizzo Davide Roccarina Antonio Gasbarrini |
| author_sort | Veronica Ojetti |
| collection | DOAJ |
| description | Introduction. Helicobacter pylori eradication therapy has the potential burden of antibiotic-associated gastrointestinal (GI) side effects. The occurrence of side effects is among the major drawbacks of such regimens. GI manifestations may be related to alterations in the intestinal microflora. Probiotics can prevent or reduce antibiotic-associated side effects and have an inhibitory effect on H. pylori. Methods. To define the efficacy of Lactobacillus reuteri supplementation in H. pylori eradication and in preventing GI-associated side effects during a second-line levofloxacin triple therapy. 90 H. pylori-positive patients receive for 7 days a second-line triple therapy with esomeprazole, levofloxacin, and amoxicillin with L. reuteri for 14 days (group 1) and without probiotic supplementation (group 2). Each subject received a validated questionnaire to record symptoms everyday for 4 weeks from the start of therapy. H. pylori status and side effects were assessed 6 weeks after treatment. Results. The eradication rate was significantly influenced by probiotic supplementation with
L. reuteri (group 1: 36/45, 80%; group 2: 28/45 62%; P<0.05). The incidence of nausea and diarrhoea in group 1 was significantly lower than that in group 2.
Conclusion. In H. pylori-positive subjects L. reuteri supplementation increases the eradication rate while reducing the incidence of the most common side effects associated with antibiotic therapy in second-line treatment. |
| format | Article |
| id | doaj-art-9f06e4cd53ad47c488e0841649db7571 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-9f06e4cd53ad47c488e0841649db75712025-02-03T01:22:09ZengWileyGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/740381740381Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line TherapyVeronica Ojetti0Giovanni Bruno1Maria Elena Ainora2Giovanni Gigante3Gianluca Rizzo4Davide Roccarina5Antonio Gasbarrini6Departement of Internal Medicine, Catholic University of Rome, 00168 Rome, ItalyDepartement of Internal Medicine, Catholic University of Rome, 00168 Rome, ItalyDepartement of Internal Medicine, Catholic University of Rome, 00168 Rome, ItalyDepartement of Internal Medicine, Catholic University of Rome, 00168 Rome, ItalyDepartement of Surgery, Catholic University of Rome, 00168 Rome, ItalyDepartement of Internal Medicine, Catholic University of Rome, 00168 Rome, ItalyDepartement of Internal Medicine, Catholic University of Rome, 00168 Rome, ItalyIntroduction. Helicobacter pylori eradication therapy has the potential burden of antibiotic-associated gastrointestinal (GI) side effects. The occurrence of side effects is among the major drawbacks of such regimens. GI manifestations may be related to alterations in the intestinal microflora. Probiotics can prevent or reduce antibiotic-associated side effects and have an inhibitory effect on H. pylori. Methods. To define the efficacy of Lactobacillus reuteri supplementation in H. pylori eradication and in preventing GI-associated side effects during a second-line levofloxacin triple therapy. 90 H. pylori-positive patients receive for 7 days a second-line triple therapy with esomeprazole, levofloxacin, and amoxicillin with L. reuteri for 14 days (group 1) and without probiotic supplementation (group 2). Each subject received a validated questionnaire to record symptoms everyday for 4 weeks from the start of therapy. H. pylori status and side effects were assessed 6 weeks after treatment. Results. The eradication rate was significantly influenced by probiotic supplementation with L. reuteri (group 1: 36/45, 80%; group 2: 28/45 62%; P<0.05). The incidence of nausea and diarrhoea in group 1 was significantly lower than that in group 2. Conclusion. In H. pylori-positive subjects L. reuteri supplementation increases the eradication rate while reducing the incidence of the most common side effects associated with antibiotic therapy in second-line treatment.http://dx.doi.org/10.1155/2012/740381 |
| spellingShingle | Veronica Ojetti Giovanni Bruno Maria Elena Ainora Giovanni Gigante Gianluca Rizzo Davide Roccarina Antonio Gasbarrini Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy Gastroenterology Research and Practice |
| title | Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy |
| title_full | Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy |
| title_fullStr | Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy |
| title_full_unstemmed | Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy |
| title_short | Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy |
| title_sort | impact of lactobacillus reuteri supplementation on anti helicobacter pylori levofloxacin based second line therapy |
| url | http://dx.doi.org/10.1155/2012/740381 |
| work_keys_str_mv | AT veronicaojetti impactoflactobacillusreuterisupplementationonantihelicobacterpylorilevofloxacinbasedsecondlinetherapy AT giovannibruno impactoflactobacillusreuterisupplementationonantihelicobacterpylorilevofloxacinbasedsecondlinetherapy AT mariaelenaainora impactoflactobacillusreuterisupplementationonantihelicobacterpylorilevofloxacinbasedsecondlinetherapy AT giovannigigante impactoflactobacillusreuterisupplementationonantihelicobacterpylorilevofloxacinbasedsecondlinetherapy AT gianlucarizzo impactoflactobacillusreuterisupplementationonantihelicobacterpylorilevofloxacinbasedsecondlinetherapy AT davideroccarina impactoflactobacillusreuterisupplementationonantihelicobacterpylorilevofloxacinbasedsecondlinetherapy AT antoniogasbarrini impactoflactobacillusreuterisupplementationonantihelicobacterpylorilevofloxacinbasedsecondlinetherapy |